Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Instructions to Figure out the Various Phases of Cellular breakdown in the lungs - 2US FDA grants market authorization to six on! PLUS nicotine pouch products
- 3'Peaky Blinders: The Immortal Man' teaser trailer reveals Cillian Murphy's Tommy Shelby back in action
- 4Watch live as near-Earth asteroid Eros buzzes the Andromeda Galaxy on Nov. 30 (video)
- 5One ant for $220: the new frontier of wildlife trafficking
- Vote in favor of Your Number one Smartwatch: Exactness and Style Matter
- Protest inspired by 'Gen Z' movement draws few young people in Mexico and many government critics
- Hilary Duff's husband responds to Ashley Tisdale's 'toxic' mom group claims: The drama, explained
- This Week In Space podcast: Episode 203 — China Rising
- PFAS in pregnant women’s drinking water puts their babies at higher risk, study finds
- Which Switch Game Do You Suggest? Share Your Decision
- Norovirus is spreading earlier again this year, wastewater data shows
- The Development of Shipping: Controlling Towards a More Associated Future
- Radiated Tortoise Faces Rapid Decline in Madagascar
